{"id":57876,"date":"2021-06-29T19:48:11","date_gmt":"2021-06-29T17:48:11","guid":{"rendered":"https:\/\/www.giuseppecaprotti.it\/?p=57876"},"modified":"2021-06-30T12:24:53","modified_gmt":"2021-06-30T10:24:53","slug":"walmart-lancia-linsulina-a-marchio-privato","status":"publish","type":"post","link":"https:\/\/www.giuseppecaprotti.it\/2019\/walmart-lancia-linsulina-a-marchio-privato\/","title":{"rendered":"Walmart lancia l’insulina a marchio privato"},"content":{"rendered":"

[vc_row][vc_column][vc_column_text]<\/p>\n

Un americano su 10 ha il diabete, pari a 34 milioni di persone (*) <\/a><\/p>\n

La maggioranza ha il diabete di tipo 2<\/strong> , causato da genetica, sovrappeso e inattivit\u00e0.<\/p>\n

Una parte di questi malati ha bisogno di insulina.<\/p>\n

Poi ci sono 1,2 milioni di americani che hanno il diabete di tipo 1<\/strong> , una malattia autoimmune\u00a0 che necessita iniezioni di insulina tutti i giorni.<\/p>\n

I clienti di Walmart<\/strong> risparmieranno dal 58% al 75% sul prezzo dell’insulina a marchio privato del gigante di Bentonville (Arkansas).<\/p>\n

Walmart<\/strong> vende medicine generiche (no logo) dal 2006.<\/p>\n

(*) 327 miliardi di dollari spesi ogni anno per il diabete,… : calcolando le perdite produttive, il sovrappeso costa all\u2019America il 9% del Pil.<\/a><\/p>\n

[\/vc_column_text][vc_zigzag][vc_column_text]<\/p>\n

\n
\n
\n

Walmart launches low-priced private label analog insulin<\/a><\/h1>\n<\/div>\n
Richa Naidu<\/a><\/div>\n<\/div>\n<\/header>\n
<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n
\n
\n
\n
\n
\"The<\/div>\n<\/div>\n<\/div>\n

The logo of Walmart is seen on shopping trolleys at their store in Sao Paulo, Brazil February 14, 2018. REUTERS\/Paulo Whitaker<\/p>\n

\n
<\/div>\n<\/div>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_column_text]<\/p>\n

CHICAGO, June 29 (Reuters) – Walmart\u00a0(WMT.N)<\/a>\u00a0said on Tuesday that it will start selling private-label analog insulin this week at a deep discount to branded insulin vials and pens, as it seeks to drive growth at its healthcare business.<\/p>\n

The product, ReliOn NovoLog, is a rapid-acting analog insulin used to control high blood sugar in adults and children with diabetes. It will require a prescription from a physician. More than two decades ago, Walmart launched a human insulin private label brand called ReliOn that costs $24.99 a vial.<\/p>\n

The world’s largest retailer said its more than 3 million customers with diabetes could save between 58% and 75% off the cash price of branded analog insulin products, or up to $101 per branded vial or $251 per package of branded FlexPen.<\/p>\n

Analog insulin tends to be more effective and easier to administer than the older, human insulin.<\/p>\n

\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n<\/div>\n

About one in 10 Americans have diabetes, or roughly 34 million people. The vast majority have type 2 diabetes, a chronic condition linked to genetics, along with weight gain and inactivity. Diet and exercise can help manage the disease, but some patients also need insulin or other medication.<\/p>\n

Alternatively, about 1.2 million people have type 1 diabetes, an autoimmune disease that requires lifelong insulin injections after the pancreas stops producing a sufficient amount.<\/p>\n

For years, patients, consumer advocates and U.S. lawmakers have complained about the high list prices for insulin and the significant out-of-pocket costs borne by patients.<\/p>\n

Walmart, which is working with pharmaceutical company Novo Nordisk\u00a0(NOVOb.CO)<\/a>, said its products were intended for use by patients with both type 1 and type 2 diabetes.<\/p>\n

\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n<\/div>\n

Bentonville, Arkansas-based Walmart has for years strategically lowered consumer prices for generic drugs, undercutting branded products sold by other retailers.<\/p>\n

In 2006, Walmart began selling some generic drugs for $4 per monthly prescription – a tactic soon adopted by a number of pharmacy operators.<\/p>\n

Reporting by Richa Naidu; Additional reporting by Chad Terhune in Los Angeles; Editing by Stephen Coates<\/span><\/div>\n

[\/vc_column_text][vc_empty_space][vc_single_image image=”28900″ img_size=”full” alignment=”center”][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Un americano su 10 ha il diabete, pari a 34 milioni di persone. La maggioranza ha il diabete di tipo 2 , causato da genetica, sovrappeso e inattivit\u00e0. Una parte di questi malati ha bisogno di insulina. Poi ci sono 1,2 milioni di americani che hanno il diabete di tipo 1 , una malattia autoimmune\u00a0 che necessita iniezioni di insulina tutti i giorni.I clienti di Walmart risparmieranno dal 58% al 75% sul prezzo dell’insulina a marchio privato del gigante di Bentonville (Arkansas).Walmart vende medicine generiche (no logo) dal 2006.<\/p>\n","protected":false},"author":1,"featured_media":57878,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[37],"tags":[203,146,71],"class_list":["post-57876","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-interventi","tag-marchio-privato","tag-marketing","tag-wal-mart","category-37","description-off"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.giuseppecaprotti.it\/2019\/wp-json\/wp\/v2\/posts\/57876","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.giuseppecaprotti.it\/2019\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.giuseppecaprotti.it\/2019\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.giuseppecaprotti.it\/2019\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.giuseppecaprotti.it\/2019\/wp-json\/wp\/v2\/comments?post=57876"}],"version-history":[{"count":8,"href":"https:\/\/www.giuseppecaprotti.it\/2019\/wp-json\/wp\/v2\/posts\/57876\/revisions"}],"predecessor-version":[{"id":57885,"href":"https:\/\/www.giuseppecaprotti.it\/2019\/wp-json\/wp\/v2\/posts\/57876\/revisions\/57885"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.giuseppecaprotti.it\/2019\/wp-json\/wp\/v2\/media\/57878"}],"wp:attachment":[{"href":"https:\/\/www.giuseppecaprotti.it\/2019\/wp-json\/wp\/v2\/media?parent=57876"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.giuseppecaprotti.it\/2019\/wp-json\/wp\/v2\/categories?post=57876"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.giuseppecaprotti.it\/2019\/wp-json\/wp\/v2\/tags?post=57876"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}